Alternate Day Fasting and Exercise in Overweight or Obese Adults

Gangnam Severance Hospital100 enrolled

Overview

Alternate day fasting is known to be helpful to control weight and have a positive effect on insulin resistance and cardiovascular risk factors. However, there have been no studies on weight reduction program combining alternate day fasting with exercise which preserves lean mass in Korea. The purpose of this randomized clinical trial is to examine the effects of alternate day fasting and exercise on weight reduction, visceral fat, and metabolic parameters in overweight or obese adults.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

100

Conditions

Overweight Obesity Diet Modification Exercise

Interventions

Alternate Day FastingBEHAVIORAL

During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each "fast day" (24 h), and consumed food ad libitum on each "feed day" (24 h). The "fast day" and "feed day" were repeated every other day, and the "fast day" occurred 3 days per week.

ExerciseBEHAVIORAL

During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 20-65 years * Body mass index (BMI) more than 23.0 kg/m² (overweight or obese for Asian populations, according to the World Health Organization) Exclusion Criteria: * Participants with weight gain more than 5kg in the last 3 months * Participants with history of bariatric surgery * Participants with secondary obesity, such as hypothyroidism * Participants with uncontrolled hypertension or type 1 diabetes * Participants who are taking anti-diabetic medications due to type 2 diabetes * Participants with hepatic disease (AST or ALT ≥200 mg/dL) * Participants with renal disease (serum creatinine ≥2.0 mg/dL) * Participants with pancreatitis or related disorders * Participants with acute infectious diseases (i.e., pneumonia, acute enteritis, or urinary infection) * Participants with chronic inflammatory diseases (i.e., rheumatoid arthritis, or lupus) * Participants with overeating behavior * Participants with history of cardiovascular diseases * Participants with history of cancer * Participants who are taking anti-obesity, anti-diabetic, diuretic, central-nervous system, antidepressant, antipsychotic, or steroid medications * Pregnant or lactating women * Participants who intake more than 30 g of alcohol daily * Night-time or shift-work workers * Participants with chronic malabsorption syndrome or cholestasis * Participants with other medical conditions that would preclude subjects from participating in exercise and physical test

Outcomes

Primary Outcomes

Change in body weight

body weight (kg)

Time frame: baseline, 8 weeks

Secondary Outcomes

Change in visceral fat

visceral fat areas (cm2) measured by fat measurement computed tomography (CT)

Time frame: baseline, 8 weeks

Change in fasting glucose

fasting glucose (mg/dL)

Time frame: baseline, 8 weeks

Change in insulin

insulin (mcIU/mL)

Time frame: baseline, 8 weeks

Change in triglyceride

triglyceride (mg/dL)

Time frame: baseline, 8 weeks

Change in high-density lipoprotein cholesterol (HDL-cholesterol)

HDL-cholesterol (mg/dL)

Time frame: baseline, 8 weeks

Change in low-density lipoprotein cholesterol (LDL-cholesterol)

LDL-cholesterol (mg/dL) calculated using the Friedewald equation

Time frame: baseline, 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.